Greenwich LifeSciences
@greenwichlifesciences.com
Greenwich LifeSciences, Inc. is a clinical-stage biopharmaceutical company focused on the development of an immunotherapy, GP2, to prevent breast cancer recurrences in patients who have previously undergone surgery.
Greenwich LifeSciences's Company Logos
Greenwich LifeSciences's Brand Colors
Hex Code
Color name
RGB
HSL
CMYK
#A91D23
Roof Terracotta
169, 29, 35
357, 71, 39
0, 83, 79, 34
#FFFFFF
White
255, 255, 255
0, 0, 100
0, 0, 0, 0
#253142
Ebony Clay
37, 49, 66
215, 28, 20
44, 26, 0, 74
About Greenwich LifeSciences
Greenwich LifeSciences, Inc. Their primary focus is to prevent breast cancer recurrences in patients who have undergone surgery. GP2 is derived from the HER2/neu protein, which is expressed in breast cancer and several other common cancers.
Multiple studies have demonstrated the safety and efficacy of GP2. Notably, a Phase IIb clinical trial revealed that patients treated with GP2 had no cancer recurrences after a median follow-up of five years, peak immunity at six months, and no serious adverse events related to treatment. Greenwich LifeSciences is currently conducting a Phase III clinical trial named Flamingo-01, aiming to replicate these promising results and continue saving lives.
In September 2020, Greenwich LifeSciences completed its Initial Public Offering on the Nasdaq Capital Market under the symbol GLSI. With a commitment to discovering and developing biotherapeutics, Greenwich LifeSciences is at the forefront of advancing patient care. For more information, please visit their website
Brand industry
Health
Company type
Suggest company type
Year founded
Suggest founded year
Company size
Suggest company size
Related Brands
Tags
Clinical-stage biopharmaceutical
Cancer immunotherapy
HER2-targeted peptide therapy
Phase III clinical trials
Breast cancer recurrence prevention
